Alphavirus Infections: Clinical Trials

17 trials for Alphavirus Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 2 unknown, 1 not yet recruiting, 1 withdrawn. 17 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 117Completed 13, Unknown 2, Not yet recruiting 1, Withdrawn 1
Phase 22Completed 1, Unknown 1

Follow Alphavirus Infections: new trials by email Literature Review of Alphavirus Infections trials Research Report on Alphavirus Infections

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers
V4020 - Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
Phase 1Not yet recruitingMedigen, Inc.392025-08-152025-07-28
Trial of an Inactivated Chikungunya Virus Vaccine
HydroVax-005 CHIKV, Placebo - Chikungunya Fever, Chikungunya Virus
Phase 1CompletedNajit Technologies, Inc.482024-11-042026-03-19
Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.
CHIK low dose, CHIK mid dose, CHIK high dose - Chikungunya, Zika
Phase 1CompletedUniversity of Oxford1202020-10-232022-03-23
Phase 1 Study of SAR440894 vs Placebo
Placebo, SAR440894 - Chikungunya Virus Infection
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)422020-10-142026-01-13
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
MVA-BN-WEV Dose 1, MVA-BN-WEV Dose 2, MVA-BN-WEV Dose 3 - Equine Encephalitis
Phase 1CompletedBavarian Nordic452019-10-072020-08-20
VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
VRC-WEVVLP073-00-VP, VRC-GENMIX083-AL-VP - Venezuelan Equine Encephalitis, Western Equine Encephalitis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)302019-04-022021-03-24
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
mRNA-1944, Placebo - Prevention of Chikungunya Virus Infection
Phase 1CompletedModernaTX, Inc.392019-01-222021-07-07
Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)
ChAdOx1 Chik - Chikungunya Fever
Phase 1CompletedUniversity of Oxford242018-07-312019-10-18
Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine
Vaccinations on Day 0, Day 28, and Day 140 - Encephalitis, Encephalitis, Viral
Phase 1UnknownSRI International482018-07-172021-02-23
Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers
VLA1553 - Chikungunya
Phase 1CompletedValneva Austria GmbH1202018-03-052019-08-29
Phase I Trial of Measles Vectored Chikungungya Vaccine
Placebo, VRC-CHKVLP059-00-VP - Chikungunya Virus Infection
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)1802017-05-302020-11-27
Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine
Inactivated Chikungunya virus vaccine 20 mcg, Inactivated Chikungunya virus vaccine 30 mcg, Inactivated Chikungunya virus vaccine 10 mcg - Chikungunya
Phase 1CompletedBharat Biotech International Limited602017-04-172020-10-28
Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins
anti-CHIKV hyperimmune immunoglobulins - Chikungunya Virus Infection
Phase 1 / Phase 2UnknownCentre Hospitalier Universitaire de la Guadeloupe402014-09-012014-11-03
Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers
Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo - Venezuelan Equine Encephalitis Virus Infection
Phase 1CompletedIchor Medical Systems Incorporated422013-12-012015-08-26
Chikungunya Virus Vaccine Trial in Healthy Adults
VRC-CHKVLP059-00-VP - Viral Vaccines, Chikungunya Fever
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)252011-12-012016-07-25
Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine
Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant - Ross River Virus Disease (RRVD)
Phase 1 / Phase 2CompletedAlachua Government Services, Inc.4002008-06-012015-10-09
Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine
VEE 3526 - Venezuelan Equine Encephalitis
Phase 1WithdrawnDynPort Vaccine Company LLC, A GDIT Company2005-07-012015-09-18

Narrower conditions

Chikungunya Fever (10)  ·  Encephalomyelitis, Venezuelan Equine (5)  ·  Encephalomyelitis, Equine (2)  ·  Virus Diseases (2)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Central Nervous System Infections (1)  ·  Central Nervous System Viral Diseases (1)  ·  Encephalitis (1)  ·  Encephalitis, Viral (1)  ·  Encephalomyelitis (1)  ·  Encephalomyelitis, Eastern Equine (1)  ·  Encephalomyelitis, Western Equine (1)  ·  Infectious Encephalitis (1)

Broader conditions

Arbovirus Infections (17)  ·  Infections (17)  ·  Mosquito-Borne Diseases (17)  ·  Vector Borne Diseases (17)  ·  RNA Virus Infections (16)  ·  Togaviridae Infections (16)  ·  Virus Diseases (15)  ·  Encephalitis, Arbovirus (6)  ·  Neuroinflammatory Diseases (6)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Central Nervous System Infections (5)  ·  Central Nervous System Viral Diseases (5)  ·  Encephalitis (5)

Interventions

Vaccines (1)  ·  aluminum sulfate (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (4)  ·  University of Oxford (2)  ·  Alachua Government Services, Inc. (1)  ·  Bavarian Nordic (1)  ·  Bharat Biotech International Limited (1)  ·  Centre Hospitalier Universitaire de la Guadeloupe (1)  ·  DynPort Vaccine Company LLC, A GDIT Company (1)  ·  Ichor Medical Systems Incorporated (1)  ·  Medigen, Inc. (1)  ·  ModernaTX, Inc. (1)  ·  Najit Technologies, Inc. (1)  ·  SRI International (1)  ·  Valneva Austria GmbH (1)

Countries

United States (12)  ·  Austria (1)  ·  Belgium (1)  ·  France (1)  ·  India (1)  ·  Mexico (1)  ·  Netherlands (1)  ·  United Kingdom (1)

Top investigators

Adrian V Hill, DPhill FRCP (1)  ·  Carlos Fierro, MD (1)  ·  Grace Chen, MD (1)  ·  Julie E Ledgerwood, D.O. (1)  ·  Julie E Ledgerwood, DO (1)  ·  Krishna Mohan, PHD (1)  ·  Nina Wressnigg (1)  ·  Sascha Goonewardena, MD (1)

Results publications

PMID 25132507, PMID 27206386, PMID 32497524, PMID 34330906, PMID 34887572, PMID 35210606, PMID 35568049, PMID 38494412

NIH funding

2014 (1), U44AI152995 (1)